CA2761150C - Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans - Google Patents

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans Download PDF

Info

Publication number
CA2761150C
CA2761150C CA2761150A CA2761150A CA2761150C CA 2761150 C CA2761150 C CA 2761150C CA 2761150 A CA2761150 A CA 2761150A CA 2761150 A CA2761150 A CA 2761150A CA 2761150 C CA2761150 C CA 2761150C
Authority
CA
Canada
Prior art keywords
alpha
oligodextran
composition
kda
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2761150A
Other languages
English (en)
French (fr)
Other versions
CA2761150A1 (en
Inventor
Thierry Naeye
Alexandra Einerhand
Michel Lopez
Susan M. Potter
Magali Remaud-Simeon
Pierre Frederic Emmanuel Monsan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tate and Lyle Ingredients France SAS
Original Assignee
Tate and Lyle Ingredients France SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tate and Lyle Ingredients France SAS filed Critical Tate and Lyle Ingredients France SAS
Publication of CA2761150A1 publication Critical patent/CA2761150A1/en
Application granted granted Critical
Publication of CA2761150C publication Critical patent/CA2761150C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C12P19/08—Dextran
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/18—Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2205/00—Polymer mixtures characterised by other features
    • C08L2205/02—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group
    • C08L2205/025—Polymer mixtures characterised by other features containing two or more polymers of the same C08L -group containing two or more polymers of the same hierarchy C08L, and differing only in parameters such as density, comonomer content, molecular weight, structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
CA2761150A 2009-05-07 2010-05-07 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans Active CA2761150C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624209P 2009-05-07 2009-05-07
US61/176,242 2009-05-07
PCT/US2010/033984 WO2010129839A1 (en) 2009-05-07 2010-05-07 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Publications (2)

Publication Number Publication Date
CA2761150A1 CA2761150A1 (en) 2010-11-11
CA2761150C true CA2761150C (en) 2017-06-13

Family

ID=42236313

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2761150A Active CA2761150C (en) 2009-05-07 2010-05-07 Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Country Status (11)

Country Link
US (3) US8816067B2 (enExample)
EP (1) EP2427499A1 (enExample)
JP (2) JP6077303B2 (enExample)
KR (1) KR101783383B1 (enExample)
CN (1) CN102439048B (enExample)
AU (1) AU2010245761B2 (enExample)
BR (1) BRPI1014800A8 (enExample)
CA (1) CA2761150C (enExample)
IL (1) IL215936A (enExample)
MX (1) MX2011011659A (enExample)
WO (1) WO2010129839A1 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427499A1 (en) 2009-05-07 2012-03-14 Tate&Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
BR112013004194A2 (pt) * 2010-08-25 2016-05-10 Tate & Lyle Ingredients produto simbiótico
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
AU2012332491A1 (en) * 2011-11-04 2014-05-29 General Mills, Inc. Methods and compositions for modulating gastrointestinal bacteria to promote health
CN104363769B (zh) * 2012-02-28 2016-08-24 康奈尔大学 益生菌组合物和方法
EP2836224A4 (en) 2012-02-29 2015-12-16 Ethicon Endo Surgery Inc COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
KR101381794B1 (ko) * 2012-04-10 2014-04-07 씨제이제일제당 (주) 타가토스 및 프로바이오틱 유산균을 함유하는 신바이오틱 식품 조성물
WO2014007606A1 (en) * 2012-07-05 2014-01-09 N.V. Nutricia Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour
US20150296851A1 (en) * 2012-11-27 2015-10-22 Shanghai Jiao Tong University Compositions for Balancing Gut Microbiota and the Preparation and the Uses thereof
US20150335615A1 (en) * 2013-01-04 2015-11-26 Toshihisa Kawai Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
AU2015223025B2 (en) * 2014-02-27 2018-09-20 Nutrition & Biosciences USA 4, Inc. Enzymatic hydrolysis of disaccharides and oligosaccharides using alpha-glucosidase enzymes
US10351633B2 (en) 2014-05-29 2019-07-16 E I Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
BR112016027887A2 (pt) 2014-05-29 2017-10-24 Du Pont composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, para produzir uma composição de carboidratos misturada, método para reduzir o índice glicêmico, método para inibir a elevação do nível de açúcar no sangue, composição cosmética, uso da composição e composição
WO2015183722A1 (en) * 2014-05-29 2015-12-03 E. I. Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
US20180049457A1 (en) 2014-05-29 2018-02-22 E I Du Pont De Nemours And Company Enzymatic synthesis of soluble glucan fiber
BR112016027849B1 (pt) * 2014-05-29 2022-02-22 Dupont Industrial Biosciences Usa, Llc Composições de fibra solúvel de a-glucano, composição de carboidrato, produto alimentício e composição cosmética farmacêutica ou com baixa cariogenicidade
MX2016015603A (es) 2014-05-29 2017-06-26 Du Pont Síntesis enzimática de fibra de glucano soluble.
CN107001528A (zh) 2014-07-09 2017-08-01 米德瑞（美国）有限公司 低聚糖组合物及其制备方法
FR3024158A1 (fr) 2014-07-28 2016-01-29 Inst Nat Sciences Appliq Proteine a activite dextrane-saccharase et applications
CA2958712C (en) * 2014-09-22 2019-11-26 Morinaga Milk Industry Co., Ltd. Slowly digestible, sustained-type energy supplying agent
CA2964480A1 (en) 2014-10-31 2016-05-06 Whole Biome Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US20160165941A1 (en) 2014-11-21 2016-06-16 Flipn'Sweet, LLC Sugar substitute compositions comprising digestion resistent soluble fiber
EP3237455B1 (en) 2014-12-22 2020-03-04 DuPont Industrial Biosciences USA, LLC Polysaccharide compositions for absorbing aqueous liquid
EP3400953A1 (en) 2014-12-23 2018-11-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
AR103260A1 (es) 2014-12-23 2017-04-26 4D Pharma Res Ltd Modulación inmunitaria
HK1246600B (en) 2015-01-26 2020-04-09 Cadena Bio, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
PT3071235T (pt) 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
CA2983236A1 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
SMT201900588T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni
NZ737752A (en) 2015-06-15 2022-02-25 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US11104747B2 (en) 2015-11-05 2021-08-31 Nutrition & Biosciences USA 4, Inc. Dextran-poly alpha-1,3-glucan graft copolymers and synthesis methods thereof
JP7045313B2 (ja) 2015-11-13 2022-03-31 ニュートリション・アンド・バイオサイエンシーズ・ユーエスエー・フォー，インコーポレイテッド 洗濯ケアおよび織物ケアにおいて使用するためのグルカン繊維組成物
WO2017083226A1 (en) 2015-11-13 2017-05-18 E. I. Du Pont De Nemours And Company Glucan fiber compositions for use in laundry care and fabric care
EP3374401B1 (en) 2015-11-13 2022-04-06 Nutrition & Biosciences USA 4, Inc. Glucan fiber compositions for use in laundry care and fabric care
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017091533A1 (en) * 2015-11-26 2017-06-01 E. I. Du Pont De Nemours And Company Polypeptides capable of producing glucans having alpha-1,2 branches and use of the same
WO2017127436A1 (en) * 2016-01-18 2017-07-27 Isothrive Llc Maltosyl-isomaltooligosaccharides
JP6785509B2 (ja) * 2016-02-24 2020-11-18 Ｎｏｓｔｅｒ株式会社 ロイコノストック メセンテロイデスが産生する菌体外多糖を有効成分として含む代謝異常の予防または治療用組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
ME03487B (me) 2016-03-04 2020-01-20 4D Pharma Plc Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CA3046207A1 (en) * 2016-12-06 2018-06-14 Kaleido Biosciences, Inc. Glycan polymers and related methods thereof
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
SMT202000555T1 (it) 2017-06-14 2020-11-10 4D Pharma Res Limited Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP3703705B1 (en) 2017-11-03 2024-05-15 DSM Nutritional Products, LLC Glucose-containing glycan preparations for use in the treatment of hyperammonaemia
EP3720967A4 (en) * 2017-12-08 2021-09-08 Isothrive Inc. METHOD FOR PRODUCING MALTOSYL ISOMALTOOLIGOSACCHARIDES (MIMO)
CN108191987B (zh) * 2017-12-28 2022-01-14 山东百龙创园生物科技股份有限公司 一种抗性淀粉的制备方法
EP3740583A1 (en) 2018-02-23 2020-11-25 Danisco US Inc. Synthesis of glucan comprising alpha-1,3 glycosidic linkages with phosphorylase enzymes
CN108912410A (zh) * 2018-06-24 2018-11-30 袁暾 一种含茶提取物的β-葡聚糖胶体
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
US20200113858A1 (en) * 2018-10-15 2020-04-16 Freedom Health, Llc Human dietary supplement and method for treating digestive system and immune-related disorders
CN113271794B (zh) 2018-10-25 2024-01-05 O·霍夫梅克勒 天然增甜风味组合物
KR20220007090A (ko) * 2019-05-08 2022-01-18 칼레이도 바이오사이언시즈, 인크. 올리고사카라이드 조성물 및 그의 사용 방법
US12508274B2 (en) 2020-07-17 2025-12-30 Dsm Nutritional Products, Llc Oligosaccharide compositions and methods of use
CN112553271A (zh) * 2020-12-15 2021-03-26 江南大学 一种含α-1,2糖苷键低热量糊精的制备方法
KR102921007B1 (ko) 2023-02-23 2026-02-02 유선균 웨이셀라 시바리아 ysk01 균주 및 이의 용도
KR20240161925A (ko) 2023-05-04 2024-11-13 단국대학교 천안캠퍼스 산학협력단 류코노스톡 메젠테로이드 mksr 유래 당전이 효소로 제조된 신규 당류, 이의 용도 및 이의 제조 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB749515A (en) * 1953-03-19 1956-05-30 Dextran Ltd Improvements in or relating to the production of dextran
FR2626583B1 (fr) * 1988-01-29 1991-03-15 Bioeurope Procede de preparation enzymatique d'oligodextranes utiles dans la fabrication de substituts du sucre, et nouveaux oligodextranes
JP3503238B2 (ja) 1995-01-09 2004-03-02 ソニー株式会社 適応型制御装置
KR100501584B1 (ko) * 2000-02-03 2005-07-18 (주)케이비피 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품
DE10105305A1 (de) * 2001-02-02 2002-08-14 Nutrinova Gmbh Sorbinsäurepräparat als Futtermittelzusatz in der Nutztieraufzucht
FR2822162B1 (fr) * 2001-03-16 2003-06-27 Inst Nat Sciences Appliq Molecules d'acides nucleiques codant une dextrane-saccharase calatalysant la synthese de dextrane portant des ramifications de type alpha-1,2 osidiques
FR2822163B3 (fr) 2001-03-16 2003-06-13 Centre Nat Rech Scient Molecules d'acides nucleiques codant une dextrane-saccharase catalysant la synthese de dextrane portant des ramifications de type alpha-1,2 osidiques
AU2002951270A0 (en) 2002-09-06 2002-09-19 Vri Biomedical Ltd Probiotic Bacterium and Methods of Use
FR2844453B1 (fr) 2002-09-13 2006-05-19 Agronomique Inst Nat Rech Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii
CN1690085A (zh) * 2004-04-30 2005-11-02 天津振和生物工程有限公司 一种水溶性多聚糖及其生产方法
FR2875406B1 (fr) 2004-09-21 2007-01-05 Danisco Souche de lactobacillus acidophilus ayant des proprietes analgesiques au niveau du systeme gastro-intestinal
FR2897069B1 (fr) 2006-02-08 2012-06-08 Centre Nat Rech Scient Construction de nouveaux variants de l'enzyme dextrane-saccharase dsr-s par ingienerie moleculaire.
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
EP1972208A1 (en) * 2007-03-16 2008-09-24 Kirin Holdings Kabushiki Kaisha Composition for improving intestinal microflora
EP2157870A1 (en) * 2007-06-25 2010-03-03 DSM IP Assets B.V. Novel prebiotics
EP2427499A1 (en) 2009-05-07 2012-03-14 Tate&Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Also Published As

Publication number Publication date
JP2016041072A (ja) 2016-03-31
CN102439048A (zh) 2012-05-02
JP6144745B2 (ja) 2017-06-07
AU2010245761A1 (en) 2011-12-01
AU2010245761A8 (en) 2012-06-07
US8816067B2 (en) 2014-08-26
CA2761150A1 (en) 2010-11-11
BRPI1014800A2 (pt) 2016-04-05
KR20120027314A (ko) 2012-03-21
US20170101484A1 (en) 2017-04-13
IL215936A (en) 2014-12-31
KR101783383B1 (ko) 2017-09-29
WO2010129839A1 (en) 2010-11-11
WO2010129839A8 (en) 2011-11-24
US10167346B2 (en) 2019-01-01
US20100284972A1 (en) 2010-11-11
AU2010245761B2 (en) 2014-10-02
BRPI1014800A8 (pt) 2016-10-11
JP6077303B2 (ja) 2017-02-08
IL215936A0 (en) 2011-12-29
EP2427499A1 (en) 2012-03-14
JP2012526145A (ja) 2012-10-25
US9512239B2 (en) 2016-12-06
MX2011011659A (es) 2012-02-28
US20150004140A1 (en) 2015-01-01
CN102439048B (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
CA2761150C (en) Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans
Ashwini et al. Reactive mechanism and the applications of bioactive prebiotics for human health
Ibrahim Functional oligosaccharides: Chemicals structure, manufacturing, health benefits, applications and regulations
Baruah et al. Functional food applications of dextran from Weissella cibaria RBA12 from pummelo (Citrus maxima)
KR102080562B1 (ko) 혈당강하 고분지형 말토덱스트린
Mussatto et al. Non-digestible oligosaccharides: A review
EP1539195B1 (fr) Prebiotiques de glucooligosaccharides pour la prevention du diabete de type ii
Śliżewska et al. Resistant dextrins as prebiotic
Gibson et al. Prebiotics
Rabiu et al. Carbohydrates: a limit on bacterial diversity within the colon
JP2010100583A (ja) 脂質代謝改善剤
EP1887017A1 (en) Prebiotic carbohydrate
Glibowski et al. Prebiotic and synbiotic foods
CN115697067B (zh) 补充有纤维的酸化乳制品及提供其的方法
Mutlu et al. Modulating of food glycemic response by lactic acid bacteria
Vaze et al. Catalytic action of alternansucrase on sucrose under in vitro simulated gastric conditions
WO2007011222A2 (en) Cholesterol-lowering food additive
Jaswal et al. Prebiotic oligosaccharide production in microbial cells
US12618052B2 (en) Enzyme composition to reduce glucose uptake without compromising taste
US20250101388A1 (en) Enzyme composition to reduce glucose uptake without compromising taste
Hughes et al. Health-functional carbohydrates: properties and enzymatic manufacture
Corwin Structural and Functional Properties of Enzymatically Modified Slow Digesting α-Glucans
TW202103580A (zh) 保持健康體重或減輕體重之非治療性方法
Montenegro Synthesis and Characterization of New Oligosaccharides with Prebiotic Activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150429

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260414

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260414